Lucie Heinzerling

Friedrich-Alexander-Universität Erlangen-Nürnberg — Germany

Medicine · Health Sciences

59h-index15.4kcitations296works6.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(119), Cutaneous Melanoma Detection and Management(67), CAR-T cell therapy research(67), Immunotherapy and Immune Responses(66), Melanoma and MAPK Pathways(57)

Publications295 total

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)
iScience·2025· 1 citedOpen Access
1039 Evaluating the prognostic impact of tebentafusp-associated cutaneous toxicities on survival in 83 uveal melanoma patients: a multi-institutional cohort study
Regular and Young Investigator Award Abstracts·2025Open Access
1037 Non-infectious sarcoid-like inflammatory granulomatous conditions (NSIGC) associated with Immune checkpoint inhibitors (ICIs) for cancer: updated results from the international ICARUS consortium
Regular and Young Investigator Award Abstracts·2025Open Access
Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients
Frontiers in Oncology·2025· 1 citedOpen Access
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis
Scientific Reports·2025Open Access
CDK4/6‐Inhibitor in Kombination mit Aromatasehemmer wirksam bei metastasiertem Hidradenokarzinom
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
European Journal of Cancer·2025· 1 citedOpen Access
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors
Cancers·2025· 3 citedOpen Access
Neoadjuvante Therapie mit Immuncheckpoint‐Inhibitoren bei Melanompatienten: eine retrospektive Real‐Life‐Studie
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025
CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025· 1 citedOpen Access
Evidence for optimal treatment of immune-related adverse events needed – should we use extracorporeal photopheresis?
Immunotherapy·2025
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025· 2 citedOpen Access
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99]
European Journal of Cancer·2025· 1 citedOpen Access
Increased serum <scp>NfL</scp> and <scp>GFAP</scp> levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors
International Journal of Cancer·2025· 2 citedOpen Access
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
Nature Communications·2025· 12 citedOpen Access
Sex-Specific Survival in Advanced Metastatic Melanoma – a Decog Study on 2032 Patients of the Multicenter Prospective Skin Cancer Registry Adoreg
SSRN Electronic Journal·2025Open Access
Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T
European Journal of Cancer·2024· 10 citedOpen Access
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
European Journal of Cancer·2024· 10 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Carola Berking(15), Lisa Zimmer(13), Jochen Utikal(13), Friedegund Meier(13), Dirk Schadendorf(13), Gerold Schuler(13), Michael Constantin Kirchberger(12), Carmen Loquai(12), Ralf Gutzmer(12), Reinhard Dummer(11), Selma Ugurel(9), Thomas Eigentler(9), Katharina C. Kähler(9), Max Schlaak(9), Jessica C. Hassel(8), Axel Hauschild(8), Markus V. Heppt(8), Paaladinesh Thavendiranathan(7), Anja Gesierich(7), Syed Mahmood(6)